The improved survival of patients with complex congenital heart diseases has led to an increased number of therapeutic interventions, from surgical procedures to cardiac catheterizations and central line placement. Because… Click to show full abstract
The improved survival of patients with complex congenital heart diseases has led to an increased number of therapeutic interventions, from surgical procedures to cardiac catheterizations and central line placement. Because these interventions often lead to access site thrombosis, less common vascular sites are sometimes used. We present the case of an 8-year-old boy with tetralogy of Fallot who underwent corrective surgery and multiple sternotomies due to tracheoesophageal problems. During the clinical course, implantation of a Mitroflow no. 19 bioprosthetic aortic valve (PALEX) at the pulmonary valve was required due to severe pulmonary regurgitation with marked right ventricular dilatation. This procedure was followed by implantation of an Epic 25-mm valve (St Jude) in the tricuspid position due to severe regurgitation and of a pacemaker due to postoperative heart block. Echocardiography and cardiac magnetic resonance imaging revealed elevated right ventricular pressure with moderate-to-severe pulmonary regurgitation and right ventricular systolic dysfunction. Computed tomography angiography showed thrombosis of both femoral systems and of the superior vena cava. We decided on percutaneous implantation of a pulmonary valve via transhepatic puncture of the right inferior hepatic vein using the AccuStick II kit (Boston Scientific). Access was obtained using a 21-G Chiba needle at the midaxillary line angled in the superior, posterior and left direction; the needle was progressively withdrawn while contrast agent was injected until the hepatic vein could be seen (Video 1 of the supplementary material). A 0.014’’ guide needle was introduced until it reached the right atrium (Figure 1A, Video 2 of the supplementary material). Using the guide, a 4.5-Fr sheath, provided in the kit, was introduced. This sheath allowed the subsequent introduction of a 0.035’’ guidewire, which enabled the sheath to be exchanged for a larger femoral introducer. The right ventricular pressure was two-thirds of that of the systemic pressure, with a systolic pressure gradient of 45 mmHg at the biological pulmonary valve. Posteroanterior pulmonary angiography with a 508 cranial angulation revealed degeneration of the implanted pulmonary valve and moderate-to-severe pulmonary regurgitation (Figure 1B, Video 3 of the supplementary material). After implantation of a highsupport guidewire in the left inferior lobe pulmonary artery, the diameters of the short introducers were progressively increased from 6 Fr to 12 Fr, with subsequent use of dilators (Cook) up to 18 Fr (Video 4 of the supplementary material). Then, a 22-mm Melody TPV (Medtronic) percutaneous valve was assembled and implanted on a 22-Fr Ensemble 20 40-mm catheter in the pulmonary position, which was then redilated with an Atlas (Bard) 20 40-mm balloon catheter. The procedure was completed successfully and without incident, and it was ensured that the pulmonary regurgitation had ameliorated and the right ventricular pressure had decreased to one-third of that of the systemic pressure (Figure 1C, Video 5 of the supplementary material). Via the 0.035’’ guidewire, the Ensemble catheter was withdrawn and a 12-Fr introducer was placed; no bleeding was evident around the introducer. To close the intrahepatic tract, absorbable hemostatic material (Cutanplast) was used in small packages, soaked in contrast agent to give fluoroscopic consistency and visibility, and placed via the introducer (Figure 2, Video 6 of the supplementary material). The patient was transferred to the pediatric intensive care unit where he was monitored for 24 hours. Abdominal ultrasound performed 6, 12, and 24 hours after the procedure showed no evidence of abdominal bleeding. Treatment of stenotic lesions and/or right ventricular outflow tract and pulmonary artery regurgitation has varied in recent years, and percutaneous implantation of pulmonary valves has acquired a greater role, given its comparable results to surgery and reduced morbidity and mortality. Patients with greater morbidity (such as the present patient) are precisely those who would benefit most from a less aggressive technique because, in tetralogy of Rev Esp Cardiol. 2018;71(10):861–876
               
Click one of the above tabs to view related content.